Innate Pharma Entered into an Exclusive License Agreement with Takeda to Develop Antibody Drug Conjugates for Celiac Disease
Shots:
- Innate will receive $5M up front, ~$410M upon achievement of development, regulatory & commercial milestones along with royalties on net sales of any commercial product
- Takeda gets an exclusive right globally to research & develop ADC using a panel of selected Innate Abs against an undisclosed target with an initial focus on Celiac disease. Takeda will lead the future development, manufacture & commercialization of any potential products developed using licensed Abs
- The lead proprietary program lacutamab, developed for advanced cutaneous & peripheral T cell lymphomas, monalizumab, an NSCLC treatment co-developed with AstraZeneca & ANKET multi-specific NK cell engagers for multiple tumor types are all included in Innate's portfolio
Ref: innate pharma | Image: innate pharma
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
